Key Takeaways
- • Bessemer Venture Partners closed $5.75 billion across two dedicated AI funds: $1.75 billion for seed and early-stage investments and $4.0 billion for growth-stage capital, representing a major institutional commitment to AI infrastructure and applications.
- • The firm has deployed over $3.0 billion into AI-native companies since 2022 and now backs more than 260 AI native enterprises, including foundation model developers (Anthropic, Perplexity), autonomous coding agents (Cognition), and vertical-specific solutions.
- • Healthcare represents a primary focus within Bessemer's AI strategy, positioned as one of the largest, most operationally complex, and most defensible venture categories, shifting from experimental proof-of-concept to mission-critical clinical and administrative infrastructure.
- • Bessemer's two-fund structure directly addresses a historical bottleneck in healthcare venture capital: bridging extended, highly regulated clinical incubation cycles through early-stage capital while maintaining sufficient reserves to scale category-defining platforms across fragmented health systems.
- • The raise reflects Bessemer's strategic pivot from its Software-as-a-Service (SaaS) era anchoring investments (Box, DocuSign, Twilio, Shopify) toward AI-native software, positioning the firm at the forefront of the AI inflection in enterprise and healthcare sectors.
Summary
Bessemer Venture Partners announced the closing of $5.75 billion in new capital across two dedicated artificial intelligence vehicles, marking a watershed moment in institutional capitalization of applied machine learning. The capital is structured as $1.75 billion for seed and early-stage companies and $4.0 billion for growth-stage enterprises, providing funding across the AI stack from infrastructure to specialized vertical applications. The announcement reflects Bessemer's aggressive pivot toward AI-native software following decades of prominence in the SaaS sector, where the firm anchored investments in category-defining enterprises including Box, DocuSign, Twilio, and Shopify.
Since 2022, Bessemer has deployed over $3.0 billion into the AI sector while backing more than 260 AI-native companies spanning multiple segments. The portfolio includes foundation model developers such as Anthropic and Perplexity, autonomous coding agents including Cognition, and enterprise workflow solutions like Legora. Within this diversified AI portfolio, healthcare represents one of the largest and most strategically valuable verticals. The intersection of healthcare and generative AI is accelerating the shift from experimental proofs-of-concept to mission-critical clinical and administrative infrastructure, creating significant value creation opportunities for well-capitalized venture platforms.
Bessemer's fund structure directly addresses a persistent challenge in healthcare venture investing: the capital intensity and regulatory complexity of clinical validation cycles. By pairing substantial early-stage capital with significant growth reserves, the firm can support healthcare AI companies through extended development and commercialization timelines while scaling category-defining platforms across fragmented health systems. This dual-fund approach positions Bessemer to capitalize on the healthcare AI inflection at both the foundation-building and scaling stages, leveraging the firm's historical expertise in enterprise software alongside deep healthcare domain knowledge.
Since 2022, Bessemer has deployed over $3.0 billion into the AI sector while backing more than 260 AI-native companies spanning multiple segments. The portfolio includes foundation model developers such as Anthropic and Perplexity, autonomous coding agents including Cognition, and enterprise workflow solutions like Legora. Within this diversified AI portfolio, healthcare represents one of the largest and most strategically valuable verticals. The intersection of healthcare and generative AI is accelerating the shift from experimental proofs-of-concept to mission-critical clinical and administrative infrastructure, creating significant value creation opportunities for well-capitalized venture platforms.
Bessemer's fund structure directly addresses a persistent challenge in healthcare venture investing: the capital intensity and regulatory complexity of clinical validation cycles. By pairing substantial early-stage capital with significant growth reserves, the firm can support healthcare AI companies through extended development and commercialization timelines while scaling category-defining platforms across fragmented health systems. This dual-fund approach positions Bessemer to capitalize on the healthcare AI inflection at both the foundation-building and scaling stages, leveraging the firm's historical expertise in enterprise software alongside deep healthcare domain knowledge.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.